Gaithersburg’s miRecule Inc. has raised $5.7 million in fresh funding, CEO Anthony Saleh told us Monday, positioning the company to start human testing for its lead candidate to treat head and neck cancer.
NIH spinout raises millions to attack drug-resistant cancers with RNA. It has big plans.
